EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors
Author:
Funder
National Cancer Institute
National Institutes of Health
U.S. Department of Defense
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference50 articles.
1. The rapidly evolving landscape of biomarker testing in non-small cell lung cancer;VanderLaan;Cancer Cytopathol.,2021
2. Tumor biomarker testing in non-small-cell lung cancer: a decade of change;VanderLaan;Lung Cancer Amst. Neth.,2018
3. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data;Jorge;Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas E Biol.,2014
4. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements;Costa;Transl. Lung Cancer Res.,2016
5. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer;Yasuda;Sci. Transl. Med.,2013
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3